Comment on Stone et al. Atypical Diabetes: What Have We Learned and What Does the Future Hold? Diabetes Care 2024;47:770–781

We thank Stone et al. (1) for their comprehensive review of atypical diabetes, across both pediatric and adult populations.


http://dlvr.it/TDb6tm

About the Artist: Saul Krotki

http://dlvr.it/TDb6dV

About the Editor: Stephanie L. Fitzpatrick, PhD: Behavioral and Social Care Interventions for Chronic Disease Prevention and Management

Stephanie Fitzpatrick knew she wanted to help people. Her mother was a phlebotomist, and as a girl growing up in Louisville, Kentucky, Fitzpatrick used to shadow her during her hospital shift. “I saw how gentle she was with her patients,” she says. “Explaining what she was doing before she drew blood, checking in on them after—my mom had an ability to make people feel at ease during a stressful time.” Fitzpatrick wanted to help people, and as a kid, a career in medicine seemed like the best way to do that. She decided to become a medical doctor.


http://dlvr.it/TDb6D2

Effect of SARS-CoV-2 Infection on Incident Diabetes by Viral Variant: Findings From the National COVID Cohort Collaborative (N3C)

OBJECTIVEThe coronavirus 2019 (COVID-19) pandemic has evolved over time by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, disease severity, treatment, and prevention. There is evidence of an elevated risk of incident diabetes after COVID-19; our objective was to evaluate whether this association is consistent across time and with contemporary viral variants.RESEARCH DESIGN AND METHODSWe conducted a retrospective cohort study using National COVID Cohort Collaborative (N3C) data to evaluate incident diabetes risk among COVID-positive adults compared with COVID-negative patients or control patients with acute respiratory illness (ARI). Cohorts were weighted on demographics, data site, and Charlson comorbidity index score. The primary outcome was the cumulative incidence ratio (CIR) of incident diabetes for each viral variant era.RESULTSRisk of incident diabetes 1 year after COVID-19 was increased for patients with any viral variant compared with COVID-negative control patients (ancestral CIR 1.16 [95% CI 1.12–1.21]; Alpha CIR 1.14 [95% CI 1.11–1.17]; Delta CIR 1.17 [95% CI 1.13–1.21]; Omicron CIR 1.13 [95% CI 1.10–1.17]) and control patients with ARI (ancestral CIR 1.17 [95% CI 1.11–1.22]; Alpha CIR 1.14 [95% CI 1.09–1.19]; Delta CIR 1.18 [95% CI 1.11–1.26]; Omicron CIR 1.20 [95% CI 1.13–1.27]). There was latency in the timing of incident diabetes risk with the Omicron variant; in contrast with other variants, the risk presented after 180 days.CONCLUSIONSIncident diabetes risk after COVID-19 was similar across different SARS-CoV-2 variants. However, there was greater latency in diabetes onset in the Omicron variant era.


http://dlvr.it/TDb5zq

Relationship Between Sensor-Detected Hypoglycemia and Patient-Reported Hypoglycemia in People With Type 1 and Insulin-Treated Type 2 Diabetes: The Hypo-METRICS Study

OBJECTIVEUse of continuous glucose monitoring (CGM) has led to greater detection of hypoglycemia; the clinical significance of this is not fully understood. The Hypoglycaemia–Measurement, Thresholds and Impacts (Hypo-METRICS) study was designed to investigate the rates and duration of sensor-detected hypoglycemia (SDH) and their relationship with person-reported hypoglycemia (PRH) in people living with type 1 diabetes (T1D) and insulin-treated type 2 diabetes (T2D) with prior experience of hypoglycemia.RESEARCH DESIGN AND METHODSWe recruited 276 participants with T1D and 321 with T2D who wore a blinded CGM and recorded PRH in the Hypo-METRICS app over 10 weeks. Rates of SDH


http://dlvr.it/TDb5mb